News
ADPT
2.890
+0.35%
0.010
Weekly Report: what happened at ADPT last week (0318-0322)?
Weekly Report · 2d ago
Weekly Report: what happened at ADPT last week (0311-0315)?
Weekly Report · 03/18 09:27
Weekly Report: what happened at ADPT last week (0304-0308)?
Weekly Report · 03/11 09:26
Don't Ignore The Insider Selling In Adaptive Biotechnologies
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) recently sold US$167k worth of shares in the company. The Co-Founder of the company, Chad Robins, sold shares at an average price of US$3.43 per share. In the last year,  insiders haven't bought any shares in Adaptive BiOTEchnologies. Insiders own about 3.1% of the Company. The company has seen some insider selling over the last 12 months. It's important to note that the company has no insider purchases over the past year.
Simply Wall St · 03/08 10:05
5 Biotech Stocks With 26% Upside Potential or More
Five biotech stocks are poised for notable growth. Nvidia (NVDA) is the standout performer in the S&P 500 Index so far this year. The biotech industry may be headed for a comeback. Each of these stocks has room to rally 26% to Wall Street's mean price target.
Barchart · 03/07 13:13
Adaptive Biotechnologies: Statement of changes in beneficial ownership of securities
Press release · 03/07 02:15
Weekly Report: what happened at ADPT last week (0226-0301)?
Weekly Report · 03/04 09:27
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2023 Update
Ole Andreas Halvorsen's 13F stock portfolio value increased from $24.64B to $27.30B in Q4 2023. New stakes in Advanced Micro Devices and Deere & Co were established, while stakes in Microsoft Corporation and Block Inc. Were sold. The largest five individual stock positions in the portfolio are Visa, United Parcel Service, APi Group, and Workday.
Seeking Alpha · 02/27 06:46
Weekly Report: what happened at ADPT last week (0219-0223)?
Weekly Report · 02/26 09:29
Adaptive Biotechnologies: A Post Earnings Assessment
Seeking Alpha · 02/25 16:41
Aristotle Capital Focus Growth Q4 2023 Commentary
Aristotle Capital Focus Growth Composite posted a total return of 15.02% gross of fees in the fourth quarter of 2023. The U.S. Equity market rebounded, as the S&P 500 Index rose 11.69% during the period. Real Estate, Utilities and Information Technology were the best-performing sectors.
Seeking Alpha · 02/25 15:40
Aristotle Capital Large Cap Growth Q4 2023 Commentary
Seeking Alpha · 02/25 15:20
Analysts’ Top Healthcare Picks: RxSight (RXST), Adaptive Biotechnologies (ADPT)
RxSight (RXST) and Adaptive Biotechnologies (ADPT) have 2 analysts maintaining Buy ratings. BTIG analyst Ryan Zimmerman maintained a Buy rating on RxSight and set a price target of $61.00. The company's shares closed yesterday at $54.95.
TipRanks · 02/20 11:20
Weekly Report: what happened at ADPT last week (0212-0216)?
Weekly Report · 02/19 09:29
Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) analysts have downgraded their near-term revenue and earnings estimates for the business. The consensus price target for the company has fallen 17% to US$7.17. The analysts have also increased their loss per share forecasts for this year. The company is now expected to grow sales slower than the wider market in 2024.
Simply Wall St · 02/17 12:06
Adaptive Biotechnologies Price Target Cut to $5.00/Share From $11.00 by Goldman Sachs
Dow Jones · 02/16 17:52
Adaptive Biotechnologies Is Maintained at Neutral by Goldman Sachs
Dow Jones · 02/16 17:52
Scotiabank Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)
TipRanks · 02/16 12:39
Adaptive Biotechnologies: Hold Rating Justified by Mixed Financial Results and Ongoing Strategic Review Uncertainty
TipRanks · 02/16 12:26
Adaptive Biotechnologies Full Year 2023 Earnings: Misses Expectations
Adaptive Biotechnologies missed revenue and earnings estimates by 1.5%. The company's shares are up 7.9% from a week ago. Revenue is forecast to grow 19% p.a. In the next 3 years. The company missed analyst estimates by 11%.
Simply Wall St · 02/16 10:13
More
Webull provides a variety of real-time ADPT stock news. You can receive the latest news about Adaptive Biotechnologies through multiple platforms. This information may help you make smarter investment decisions.
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine (IM) platform combines a suite of chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its clinical diagnostic product, clonoSEQ, is used for the detection and monitoring minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). The IM business consists of two areas: IM Pharma Services and Drug Discovery. Its immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA).